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In the last three decades in the United States the preva-
lence of overweight/obesity in pediatric population has
more than tripled, causing the onset also in pediatric age
of diseases previously considered exclusively of adults,
such as metabolic syndrome (MetS) [1]. MetS represents
a cluster of cardiometabolic abnormalities, including visc-
eral obesity, dyslipidemia, hypertension and diabetes mel-
litus type 2 (T2DM) (Table 1). The prevalence of
pediatric MetS ranged from 2% to 9% in the general
population and from 12% to 44% in obese children,
depending of definition used [1]. Several evidences sug-
gest that the metabolic derangements observed in chil-
dren may have a worrisome repercussion early on their
health in adulthood [2,3].
Lifestyle modification, represented by the association
among regular physical exercise and a balanced diet
appropriate for age, is the most important therapeutic
approach in children and adolescent with obesity and risk
factors for MetS [4]. Behavioral intervention is mandatory
but, in many cases, it is difficult to achieve or not sufficient
and most pediatric patients require pharmacologic therapy
early in their disease course. At the present time, the vast
majority of drugs needed to treat insulin-resistance,
hypercholesterolemia, hypertension are off-label in pedia-
tric setting, although several studies demonstrated that
pharmacological treatment for pediatric obesity and its
related comorbidities are necessary [5].
Regarding dyslipidemia, the use of oral statins is
reserved for children older than 10 years of age that,
while on diet, continue to have dyslipidemia associated to
family history for early cardiovascular disease (CVD) or
additional risk factors.
Metformin is the only drug approved for treatment of
impaired fasting glucose (IFG) or impaired glucose toler-
ance (IGT) in children. Several studies demonstrated its effi-
cacy in ameliorating gluco-insulinemic profile; moreover,
it has been reported a moderately effect on body weight in
obese children.
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Table 1 Diagnostic criteria for metabolic syndrome in children and adolescents
IDF criteria
Age (years) 6-9 10-15 >15 (adult criteria)
Waist
circumference
≥90th percentile for age (MS as
entity is not diagnosed)
≥90th percentile or adult
cut-off if lower
≥94 cm for males,





Systolic ≥130 or diastolic ≥85 mmHg or treatment of previously
diagnosed hypertension
Triglycerides ≥1.7mmol/L (≥150 mg/
dL)
≥1.7mmol/l (≥150 mg/dL)or specific treatment for high triglycerides
HDL-C < 1.03 mmol/L (<40
mg/dL)
< 1.03 mmol/L (<40 mg/dL) in male and 1.29 mmol/L (<50 mg/dL) in
females or specific treatment for low HDL-C
Fasting
glucose
5.6 mmol/l (100 mg/dL) 5.6 mmol/l (100 mg/dL) or known T2DM
IDF: International Diabetes Federation
HDL Cholesterol: High-density lipoprotein cholesterol
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Anti-hypertensive drugs, such as angiotensin-convert-
ing-enzyme inhibitors (ACEIs), angiotensin-receptor
blockers (ARBs), calcium channel blockers (CCBs), and
beta-blocking agents are used in pediatric patients and
the choice of drug class is made on the basis of clinical
characteristics of the single patient.
The core of treatment of pediatric MetS is abdominal
obesity. Currently no pharmacological approach to obesity
is accepted for pediatric patients. Bariatric surgery has
been considered a successful treatment for MetS in obese
adults in term of weight loss and decrease of mortality
rate. This procedure has been used also in carefully
selected obese adolescents and the outcomes seem to be
similar to those for adults. However, further studies are
needed to better select the patients to surgically treat and
define efficacy and safety of bariatric surgery in pediatric
MetS.
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